Zilovertamab Adds Pharmacology, Not Broad CLL Efficacy

Company Oncternal Therapeutics / UC San Diego Event Type Clinical Data / Phase 1b/2 Publication Modality Anti-ROR1 Monoclonal Antibody + BTK Inhibitor Asset Zilovertamab + Ibrutinib Target ROR1 / BTK Disease Area Chronic Lymphocytic Leukemia Summary A peer-reviewed Phase 1b/2 study of zilovertamab plus ibrutinib…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline